Get the Stockscreener App
4.43
4.24%
0.18
After Hours:
4.44
0.01
+0.23%
Humacyte Inc stock is traded at $4.43, with a volume of 2.01M.
It is up +4.24% in the last 24 hours and down -12.62% over the past month.
See More
Previous Close:
$4.25
Open:
$4.25
24h Volume:
2.01M
Relative Volume:
0.67
Market Cap:
$570.00M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-5.092
EPS:
-0.87
Net Cash Flow:
$-75.59M
1W Performance:
+0.68%
1M Performance:
-12.62%
6M Performance:
-33.58%
1Y Performance:
+69.73%
1-Day Range:
$4.245
$4.44
1-Week Range:
$4.175
$4.645
52-Week Range:
$2.4512
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.43 | 570.00M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.98 | 119.49B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.26 | 82.89B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
624.96 | 37.37B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.72 | 32.85B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.70 | 27.50B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte director Michael Constantino purchases $20,181 in stock - Investing.com India
Humacyte director Michael Constantino purchases $20,181 in stock By Investing.com - Investing.com Australia
The Gross Law Firm Announces the Filing of a Securities - GlobeNewswire
DEADLINE ALERT for HUMA, XRX, and ZETA: The Law Offices of - GlobeNewswire
Thrivent Financial for Lutherans Acquires New Shares in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, - GlobeNewswire
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humacyte, Inc.- HUMA - PR Newswire
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - GlobeNewswire
Humacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel - GlobeNewswire
Robbins LLP Urges HUMA Stockholders with Large Losses to - GlobeNewswire
Kirby McInerney LLP Reminds Humacyte (HUMA) Investors of Class Action Filing and Encourages Investors to Contact the Firm - Business Wire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - PR Newswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - PR Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, - GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Lelezard
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure - The Bakersfield Californian
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - Benzinga
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - AccessWire
Finansavisen - Finansavisen
Kirby McInerney LLP Reminds Humacyte, Inc. (HUMA) Investors - GlobeNewswire
The Gross Law Firm Reminds Humacyte, Inc. Investors of the - GlobeNewswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA LAWSUIT ALERT: Levi Korsinsky Notifies Humacyte, Inc. | Trending From Our Network - Chicago Star Media
HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman - GlobeNewswire
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Receives $11.00 Average Target Price from Analysts - MarketBeat
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire
HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025 - The Globe and Mail
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead - The Bakersfield Californian
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA - Morningstar
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) - The Manila Times
Humacyte sees success in dual emergency-engineered tissue trials - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Announces the Filing of a Securities Class Ac - GuruFocus.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - Marketscreener.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
3.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):